Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 25; no. 5; pp. 1032 - 1037
• Main Authors: Falcone, Colomba, Emanuele, Enzo, D’Angelo, Angela, Buzzi, Maria P, Belvito, Chiara, Cuccia, Mariaclara, Geroldi, Diego
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01.05.2005; Hagerstown, MD Lippincott
• Subjects: Aged; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; Biomarkers - blood; Blood and lymphatic vessels; Cardiology. Vascular system; Coronary Artery Disease - blood; Coronary Artery Disease - epidemiology; Coronary heart disease; Diabetes Mellitus; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Heart; Humans; Lipids - blood; Logistic Models; Male; Medical sciences; Middle Aged; Prevalence; Receptor for Advanced Glycation End Products; Receptors, Immunologic - blood; Risk Factors; Solubility; Vascular disease; Human; coronary artery disease; soluble receptor for advanced glycation end products; Atherosclerosis; Risk factor; Cardiovascular disease; Product; Coronary heart disease; Glycation
• ISSN: 1079-5642; 1524-4636
• DOI: 10.1161/01.ATV.0000160342.20342.00

OBJECTIVE—The receptor for advanced glycation end products (RAGE) is a cell surface receptor whose signaling pathway has been implicated in atherogenesis. RAGE has an endogenous secretory receptor form, called soluble RAGE (sRAGE), that could exert antiatherogenic effects by acting as a decoy. We sought to determine whether a decreased plasma level of sRAGE could be independently associated with the prevalence of coronary artery disease (CAD) in nondiabetic men. METHODS AND RESULTS—Plasma levels of sRAGE were determined in 328 nondiabetic male patients with angiographically proved CAD and in 328 age-matched healthy controls. The concentration of sRAGE in plasma was significantly lower (P<0.0001) in CAD cases [median (interquartile range)966 (658–1372) pg/mL] than in control subjects [1335 (936–1954) pg/mL]. In logistic regression analysis, the multivariate-adjusted odds ratio for the presence of CAD was 6.719 (95% confidence interval, 3.773 to 11.964; P<0.0001) when the lowest quartile of the sRAGE level was compared with the highest quartile. CONCLUSIONS—Our findings indicate that low levels of sRAGE in plasma are independently associated with the presence of CAD in nondiabetic men and suggest that sRAGE is one of the clinically important molecules associated with atherosclerosis.